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Management of nodal indolent (non marginal-zone)
non-Hodgkin’s lymphomas: practice guidelines from
the Italian Society of Hematology, Italian Society of
Experimental Hematology and Italian Group for Bone
Marrow Transplantation
Non-Hodgkin’s lymphomas (NHL)account for 4% of all cancers:1 ofthese, about 40% are indolent
NHL, which are characterized by a long
disease course.2,3 The median survival of 8-
9 years4,5 has improved slightly in the last
20 years,6,7 but lymphoma continues to be
the principal cause of death in these
patients. New strategies have recently
been introduced into the therapy of indo-
lent NHL and the integration of older and
more recent research results may lead to
conflicting conclusions resulting in large
variation in clinical practice.
In order to offer the best available treat-
ments to patients, since 2001 the Italian
Society of Hematology (SIE) has been sup-
porting the development of clinical prac-
tice guidelines in the therapy of selected
hematologic diseases. In 2002, the Italian
Society of Experimental Hematology
(SIES) and the Italian Group for Bone
Marrow Transplantation (GITMO) shared
this aim with SIE and chose to focus their
efforts on the therapy of nodal indolent
NHL. Here we present the guidelines pro-
duced during this project. The guidelines
are intended to support the clinical practice
of hematologists, oncologists and




The Italian Society of Hematology
charged two chairmen (ST and GB) with
the development of the present guidelines.
They invited an Expert Panel of eight sen-
ior hematologists, selected for their expert-
ise in research and clinical practice of NHL.
An Advisory Committee was given the
duty to perform the systematic review of
literature and to guide the consensus phas-
es of developing the guidelines.
Literature search
The Advisory Committee searched the
following evidence bases: PubMed,
CancerLit, Cochrane Library, EMBASE.
The basic searching strategy adopted was:
From the Laboratorio di
Epidemiologia Clinica, IRCCS
Policlinico S. Matteo, Pavia
(GB, MM); Divisione di Ematologia e
Centro Trapianti, Azienda Ospedaliera
San Martino, Genova, (AC); Divisione
di Ematologia, IRCCS Policlinico
S.Matteo, Pavia (ML); Dipartimento
di Botecnologie Cellulari ed
Ematologia,Cattedra di Ematologia,
Università La Sapienza, Roma
(MM); Divisione di Ematologia,
Spedali Riuniti, Bergamo, (AR);
Cattedra di Ematologia, Azienda
Ospedaliera San Giovanni Battista,
Torino, (CT); Divisione di Ematologia,
Azienda Ospedaliera San Giovanni
Battista, Torino, (UV); Istituto di
Ematologia ed Oncologia Medica




Laboratorio di Epidemiologia Clinica,
IRCCS Policlinico S. Matteo,
viale Golgi 19, 27100, Pavia, Italy.
E-mail: barosig@smatteo.pv.it
The Italian Society of Hematology (SIE) and the two affiliated societies (SIES and GITMO)
commissioned a project to develop clinical practice guidelines for the treatment of nodal
indolent non-Hodgkin’s lymphomas (NHL). Key questions clinically relevant to the manage-
ment of patients with nodal indolent NHL were formulated by an Advisory Committee and
approved by an Expert Panel composed of eight senior hematologists. After a comprehen-
sive, systematic review of the literature, the Expert Panel formulated therapy recommenda-
tions and graded them according to the supporting evidence. An explicit approach to con-
sensus methodologies was used for evidence interpretation and for providing recommenda-
tions based on poor evidence. The Expert Panel formulated recommendations on when to
start a lymphoma-specific therapy, which first-line therapy to choose and which therapy to
adopt for patients with relapsed, refractory and transformed disease. Treatment deferral
was recommended for patients with stage III-IV disease without systemic symptoms, high
tumor burden, extranodal disease, cytopenia due to marrow involvement, leukemic phase,
serous effusion and high lactate dehydrogenase levels. Patients with stage I-II disease and
a low tumor burden should receive frontline external involved-field radiotherapy, while
patients with a high tumor burden or a severe prognostic score should receive front-line
chemotherapy plus involved-field radiotherapy. Younger patients with stage III-IV disease
should receive front-line therapy with anthracycline- or fludarabine-based regimens com-
bined with rituximab, while older patients who are candidates for treatment should receive
single-agent alkylating therapy. By using a systematic literature review and an explicit
approach to consensus among experts, recommendations for the key therapeutic decisions
in patients with nodal indolent NHL are provided.
Key words: non-Hodgkin’s lymphoma, clinical practice guidelines, systematic review,
rituximab, chemotherapy 
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Lymphoma/therapy* in MESH. The major hematology,
oncology and general medicine journals (Blood,
Journal of Clinical Oncology, British Journal of
Haematology, Bone Marrow Transplantation,
Haematologica, New England Journal of Medicine,
Lancet) were manually searched for relevant papers
published from 1992 to 2005. Additionally, the pro-
ceedings of the latest annual meetings were searched
for relevant unpublished evidence: American Society
of Hematology (1998-2004), Italian Society of
Hematology (2001, 2003), European Haematology
Association (2002-2004), American Society of Clinical
Oncology (2000-2004). The inquiry was updated to
March 1st, 2005. The full reference list (including the
abstracts of full papers) is available on request from
marchettim@smatteo.pv.it.
Evidence analysis
During the first meeting between the Advisory
Committee and the Expert Panel were identified the
key therapeutic questions for development of guide-
lines. The Advisory Committee members performed
a systematic literature review by selecting the rele-
vant pieces of evidence and grading their quality. The
grading system chosen for the present guidelines is
the one produced by the Scottish Intercollegiate
Guideline Network (SIGN):8 this system primarily
classifies evidence according to the study design, thus
assigns randomized trials to level 1, cohort and case-
control studies to level 2, and case reports to level 3.
Studies belonging to level 1 and 2 are further classi-
fied into three levels, namely ++, + and -, according to
the study and reporting quality. We modified the
original classification so as to account for phase II
studies, which were assigned level 2, as for cohort
studies. Relevant studies (i.e. randomized clinical tri-
als) reported in abstract form only could not be
assigned a quality level, but were uniquely classified
according to their study design. 
Formulation of recommendations
Each member of the Expert Panel formulated rec-
ommendations pertinent to a specific key question.
For any statement the expert qualified the strength of
evidence supporting the recommendation. When no
evidence at all was available, the expert suggested
expertise-based recommendations.
In order to reach the final set of recommendations,
an explicit approach to consensus methods was
devised. A first round of consensus on the recommen-
dations proposed by any individual expert was
obtained through paper questionnaires, according to
the Delphi Panel technique.9 The Expert Panel
expressed the degree of agreement on any individual
recommendation with comments. The final round of
consensus was organized through the nominal group
technique10 along three consensus conferences.
Participants at the consensus conferences were indi-
vidually asked to rate each recommendation, the
interpreted strength of evidence and the link between
the recommendation and the supporting evidence as
appropriate or not appropriate. If an 80% consensus
was not achieved, the recommendation was dis-
cussed in round-robin fashion and a second vote
taken. If an 80% consensus was still not attained, the
problem was declared unresolvable and was not con-
sidered further.
All the recommendations were graded class A if
supported by consistent and applicable level 1 evi-
dence (at least one level 1++ trial or some consistent
level 1+ trials), class B if evidence was derived from
consistent results of level 2++ studies or was extrapo-
lated from level 1+/1++ trials, class C if supported by
grade 2+ studies that could be applied directly to the
object population and provided consistent results, or
level 1++ studies from different populations (translat-
ed evidence), and grade D when supported by poor
quality evidence or evidence extrapolated from grade
2+ studies, and thus sustained mainly by the experts’
opinion.
Draft guidelines were reviewed by an external
panel of expert radiotherapists and by the presidents
of the three scientific societies, i.e. SIE, SIES and
GITMO.
The present guidelines are intended to be updated
in 2007.
Definitions
The Expert Panel agreed on the following defini-
tions to be used in the present guidelines:
Indolent NHL: including follicular lymphoma grade
1-2 and small-cell lymphocytic lymphoma in the
absence of criteria for a diagnosis of chronic lympho-
cytic leukemia (defined according to the modified
NCI criteria).11 Immunocytoma, Waldenström’s dis-
ease and nodal/splenic marginal zone lymphoma
were excluded from the present guidelines.
Stage: the Ann Arbor staging system was consid-
ered.12
High tumor burden: tumor burden was defined by the
presence of at least one of the following features:13
nodal/extranodal tumor mass > 7 cm, ≥3 nodal sites,
each with a nodal diameter >3 cm; any B symptoms;
splenic enlargement with inferior margin below the
line of the umbilicus; serous effusion; compression
syndrome (ureteral, orbital, gastrointestinal);
leukemic phase (> 5¥109/L circulating lymphoma
cells).
Transformed lymphoma: histologic transformation
was interpreted as the onset of any area of diffuse
large B-cell lymphoma in a follicular lymphoma.14
Elderly patients: patients aged 65 years or older were
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considered elderly. However, the Expert Panel recom-
mended that performance status and comorbidities
should also be taken into account in treatment deci-
sions.
Response criteria. Definitions of clinical response are
reported in Table 1.15 It should be noted that most of
the reported evidence did not adhere to these recent
response criteria.
Complete molecular response: sustained polymerase
chain reaction negativity.
Risk scoring systems: The International Prognostic
Index (IPI),16 the Italian Lymphoma Intergoup (ILI),5
and the Follicular International Prognostic Index
(FLIPI)17 risk scoring systems were adopted to stratify
patients, when appropriate.
Results
Indications to start treatment
The indication to start treatment in patients with
nodal indolent NHL was evaluated by three trials that
randomized patients with de novo, asymptomatic,
advanced-stage and low tumor burden indolent NHL
to either chemotherapy or a strategy of watchful
waiting.18-20 Two level 1- old trials compared watchful
waiting with ProMace-MOPP polychemotherapy,18
prednimustine or interferon19 in stage II-IV patients
and did not show any significant difference in 4- and
5-year survival, respectively, except for a significant
prolongation of failure-free survival with poly-
chemotherapy.18 A more recent randomized trial
(level 1+)20 with a 16-year median follow-up, reported
that median overall survival was 5.9 years for patients
treated with oral chlorambucil versus 6.7 years
(p=0.84) for those whose management was limited to
observation. Cause-specific survival was also similar
in the two arms: 9 vs 9.1 years, respectively. The
median time to first systemic treatment was 2.7 years
in the group randomized to watchful waiting. At mul-
tivariate analysis, age younger than 60 years, erythro-
cyte sedimentation rate 20 mm/h or less, and stage III
disease conferred a significant advantage in both
overall survival (p<0.0001, 0.03, and 0.03, respective-
ly) and cause-specific survival (p=0.002, 0.008, and
0.001, respectively).20
A strategy of watchful waiting for patients with
localized stage disease was evaluated by only two
level 2 studies.21,22 The first one reported the outcome
of 26 patients with stage I indolent NHL followed
without any therapy after removal of all evident dis-
ease by diagnostic biopsy.21 The overall survival rate
of the population at 5 and 7 years was 82.5% and
69%, respectively, and 50% of the patients were
relapse-free after a median follow-up of 4.6 years. In
a second retrospective study, 43 patients with
Table 1. Response criteria for lymphoma (adapted from: Cheson, J Clin Oncol 1999).15
Response Category Lymph Nodes Other sites Bone Marrow
Complete Response (CR) Regression to £  1.5 cm GTD in nodes >1.5 cm Regression or maintenance of normal size Normal
before therapy and to £ 1 cm GTD
(or by more than 75% SPD) in nodes
1.1-1.5 cm before therapy
Complete Response Possible residual nodes >1.5 cm GTD but with Regression or maintenance of normal size Normal or inde
undefined (CRu) a SPD regression of >75% terminate
(increased number or size 
of aggregates without
cytological or achitectural atypia)
Partial Response (PR) µ50% decrease in SPD Spleen and liver: no increase in size; Irrelevant
of the 6 largest nodes or nodal regression by >50% in nodules
masses and no increase in size No new sites of disease.
of other nodes
Relapse 
(for patients with CR or Appearance of any new nodes and/ Appearance of any new lesion Appearance or reappearance 
Cru at the end of therapy) or increase by µ  50% in the size and/or increase by ≥ 50% of involvement
of previously involved nodes in the size of previously involved sites
Progression µ50% increase from nadir in SPD Appearance of any new lesion Appearance or reappearance 
(for patients on therapy of any previously abnormal node of involvement
or with PR or non-responders at
the end of therapy)
GTD: greatest transverse diameter; SPD: sum of the products of the greatest diameter.
untreated stage I and II follicular lymphoma deferred
initial therapy for various reasons.22 Only 16 (37%)
patients received any treatment within 7 years from
the diagnosis. The estimated 10-year overall survival
rate was 85% after a median follow-up of 86 months.
After a review of 21 observational studies docu-
menting that median overall survival exceeded 10
years,23-42 the Expert Panel judged that the evidence
provided from these studies recommends that a strat-
egy of watchful waiting is appropriate only in
patients with advanced disease. These results were
especially valuable in elderly patients, in whom qual-
ity of life and non-lymphoma-related causes of death
are more relevant. The same conclusion cannot be
completely supported for younger patients, since the
existing evidence in favor of this strategy does not
account for novel therapies and the chance of needing
chemotherapy is high in a short time frame. The only
possible exceptions are patients with limited disease
without residual lymphoma after excisional biopsy,
who attain a very good outcome despite no further
treatment.
Recommendations
Treatment can be safely deferred without disadvantage to
survival for patients with stage III-IV disease, provided that
none of the following features occurs: systemic symptoms,
high tumor burden, extranodal disease, cytopenia due to
marrow involvement, spleen involvement, leukemic phase,
serous effusion, erythrocyte sedimentation rate > 20 mm/h,
high lactate dehydrogenase levels [grade A]. A policy of
watchful waiting is particularly advisable in elderly patients
(> 70 years) with the above characteristics [grade B].
Patients with stage I-II disease should not be managed
with a frontline strategy of watchful waiting; however elder-
ly patients with stage I disease and no symptoms whose lac-
tate dehydrogenase level is not elevated may be safely
observed without treatment, provided that there is no resid-
ual disease after excisional biopsy [grade D].
First-line therapy
Localized stage I-II
The Advisory Committee selected for review 14
papers addressing radiation therapy as the sole treat-
ment for this group of patients. The definitions used
in literature for the radiation fields vary considerably.
Involved field radiotherapy is most commonly used in
localized lymphomas and implies treatment to the
nodal region or extranodal sites and, if involved, its
immediate lymph node drainage area. A treatment
plan including the adjacent, second echelon not
involved lymph nodes is usually considered extended
field radiotherapy, even if true extended field therapy
should refer to the classical Hodgkin’s fields.
Evidence on radiotherapy in localized stage I-II dis-
ease was derived mostly from poor quality phase II
studies or case series.23-36 Patients wiith stage I and II
follicular lymphoma treated with a radiation dose of
30 to 36 Gy delivered in 15 to 20 fractions over 2-4
weeks experienced local control rates of more than
95%. Moreover, radiation therapy alone achieved
excellent survival and long-term disease control: in a
recent update of the Princess Margareth Hospital
experience,23 overall survival rates at 5 and 10 years
were 79% and 62%, while disease-free survival rates
were 56% and 41%, respectively. Several retrospec-
tive papers showed similar clinical outcomes, with 5-
year overall survival rates ranging from 70% to
90%.24-36 There is insufficient information to assess
the impact of doses lower than 30 Gy on local control
in unselected cohorts of patients with follicular lym-
phoma. Six randomized level I-II trials37-42 reported
that the addition of chemotherapy to first-line radio-
therapy does not prolong survival in patients with
stage-I-II NHL; however, only one trial, employing
chlorambucil, selectively enrolled and analyzed low-
grade NHL patients.42 Phase II studies from the MD
Anderson Center43-46 reported a very high failure-free
survival, i.e. 76% at 10 years, with COP/CHOP-like
chemotherapy added to involved field radiotherapy,
which was about 20-25% higher than the rate
achieved with involved field radiotherapy alone.
Within the subset of patients with limited stage I-II
disease, high tumor burden and high risk (IPI>1 or ILI
>2) were considered negative predictors of progres-
sion-free survival in three phase II studies.34,36,46
Moreover, the Expert Panel judged that long-term
toxicity should be a relevent criterion for choosing
either involved field or extended field radiotherapy
and that the involved field approach should therefore
be considered a standard in the setting of stage I-II fol-
licular lymphoma. The Expert Panel deemed the
strength of evidence sufficient to recommend front-
line chemotherapy followed by involved field radio-
therapy only in stage I-II patients with a high tumor
burden.
An innovative approach to the treatment of local-
ized stage disease with low tumor burden might be
the association of immunotherapy (rituximab) with
radiotherapy. So far, no studies have been reported
which compare radiotherapy alone to the combina-
tion of radiotherapy and rituximab.
Advanced stage III-IV
Extended field radiotherapy alone has been evaluat-
ed in stage III follicular lymphoma in three retrospec-
tive phase II studies (grade 2).47-49 The median overall
survival was about 10 years. In the Stanford study,49
the subset of patients with limited stage III disease
(defined as fewer than 5 disease sites, tumor masses
less than 10 cm and no B symptoms), showed a bet-
ter outcome, i.e. a failure-free survival rate of 88% at
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over 23 years follow-up. Two randomized studies
(grade 1)50,51 compared chemotherapy alone with a
combined approach (chemotherapy plus extended
field radiotherapy), or central lymphatic irradiation
alone versus chemotherapy alone. In the first study
(grade 2+),50 the long term follow-up showed that the
combined approach achieved significantly better dis-
ease control, but not significantly longer overall sur-
vival or failure-free survival. In the second (grade 2-),51
the two arms showed similar overall survivals and
relapse-free survivals, but a significantly higher rate of
molecular remissions was achieved by chemothera-
py.51 The rate of second malignancies reported in the
first study was low in both the treatment arms,50
while a significantly higher rate of secondary cancers
was reported in patients receiving central lymphatic
irradiation. 51
Because of the high risk of secondary cancers with
extended radiotherapy/central lymphatic irradiation,
as compared with chemotherapy alone, the Expert
Panel judged radiotherapy not to be a valuable first-
line therapy in patients with advanced disease.
However, extended-field radiotherapy alone could be
of benefit to selected patients with limited stage III dis-
ease, provided that they prefer to avoid chemothera-
py or when an absolute contraindication to
chemotherapy exists. 
The Advisory Committe analyzed 37 randomized
trials comparing different regimens of chemotherapy
in advanced stage indolent lymphomas. Seven studies
compared alkylating agents, 12 anthracycline-based
chemotherapies, 4 purine analogs and 14 CVP-like
regimens. Single agent chemotherapy with chloram-
bucil or cyclophosphamide was widely used in
advanced stage indolent lymphomas. Both drugs are
able to induce an overall response rate ranging from
54-72% with a complete response rate from 30 to
70% and a median overall survival ranging from 4.5
to 9 years.52-55
Single agent chemotherapy was compared to poly-
chemotherapy with or without an anthracycline:
although some studies reported a higher response rate
with polychemotherapy, neither cyclophosphamide-
containing regimens, such as CVP,56-58 nor anthracy-
cline-containing regimens 59-61 were able to produce a
better outcome than that afforded by single agent
chemotherapy. These data were confirmed in a sys-
tematic review of 8699 patients.62 Although chloram-
bucil toxicity is limited, long-term exposure to cumu-
lative alkylating doses may induce impairment of
peripheral blood stem cell mobilization and a higher
risk of secondary myelodysplasia.63,64 On the basis of
the evidence on adverse events, the Expert Panel
judged that single agent chemotherapy should be
avoided in young patients.
Adriamycin was introduced in the 1980s within
polychemotherapy regimens such as CHOP: since
then, five prospective and one retrospective study
have reported outcomes of first-line therapy with
CHOP in a total of 1,343 patients.65-71 Consistent data
are lacking on superior outcomes with CHOP as com-
pared with CHOP-like regimens or with CVP-like
regimens.72,74 
Good outcomes have been reported for other
anthracycline-based regimens: in the SWOG 8809
trial,75 ProMACE-MOPP achieved some kind of
response in 83% of the patients and COPA in 86%.76
However, the addition of epirubicin to chlorambucil
did not improve either the response rate or survival in
non-follicular indolent NHL, as reported by a recent
randomized trial by the Italian Lymphoma
Intergroup.59
In the nineties, purine analogs became available for
clinical research.77 Single-agent therapy with fludara-
bine showed efficacy in indolent lymphoma with an
overall response rate of 60-70% and a complete
response rate of 30-37%.78,79 In an EORTC random-
ized trial, fludarabine produced significantly better
overall and complete response rates than did CVP;
however, neither time to progression nor overall sur-
vival differed between the two arms.80 Fludarabine-
containing regimens with anthracyclines (mitox-
antrone ± dexamethasone or idarubicin)81-85 or
cyclophosphamide86-88 were able to induce a high
overall response rate (from 81% to 94%) with com-
plete response rates ranging from 39% to 79% and a
4-year progression-free survival from 38% to 90%.
Moreover, fludarabine used in combination with
mitoxantrone (FM), or with mithoxantrone and dex-
amethasone (FND) induced bcl2 rearrangement nega-
tivity in 21% to 56% of patients.82,85,86 A comparison
across phase II studies suggested that fludarabine
used in combination was more effective than fludara-
bine alone, however the only randomized trial com-
paring single-agent fludarabine with fludarabine in
combination with idarubicin yielded comparable
response rates, although the progression-free survival
rate was better in the combination arm.81 The effec-
tiveness of FM or FND was compared to that of
CHOP-like regimens in three recent randomized tri-
als.86, 89, 90 In an Italian randomized trial,86 frontline FM
provided higher complete response and molecular
response rates than did the CHOP chemotherapy reg-
imen. However, no survival data are currently avail-
able in support of a better outcome with FM.
Although fludarabine is a well tolerated agent,
adverse effects include the risk of opportunistic infec-
tion, mainly Pneumocystis carinii, and impairment of
peripheral blood cell mobilization. Evidence on the
optimal strategy for infection prophylaxis was
derived only from retrospective studies (grade 2).91,92
These studies documented that lack of Pneumocystis
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carinii prophylaxis was the only significant variable
that differentiated patients who developed oppor-
tunistic lung infections from those who did not, and
that corticosteroid treatment was associated with an
increased risk of opportunistic infections. After dis-
cussion, the Expert Panel agreed on the wisdom of
prophylactic treatment with trimethoprim sul-
phamethoxazole, at least in patients receiving flu-
darabine and concomitant steroids. Impaired stem
cell mobilization after fludarabine-containing regi-
mens was reported by a few studies,93-95 and these
results did not concord with those of other studies.89
One randomized trial (level 1-) showed that front-
line single-agent interferon did not significantly
improve progression-free or overall survival, com-
pared to a strategy of watchful waiting or single agent
chemotherapy.19 Several randomized trials proved
that the association of interferon with mono-
chemotherapy or polychemotherapy not containing
doxorubicin did not improve overall or complete
response rate and was more toxic.96-98 Interferon com-
bined with doxorubicin-based chemotherapy (CHVP
or COPA) was reported to increase progression-free
survival;76,99 however, overall survival was significant-
ly prolonged in only one trial.13 Combining interferon
with CHVP polychemotherapy significantly
improved response rate, failure-free survival and
overall survival in comparison to fludarabine as a sin-
gle-agent.79 However, 39% of the patients allocated to
interferon combination therapy dropped out because
of severe fatigue or toxicity. In a meta-analysis of
eight randomized trials, significant improvements in
5-year overall survival and progression-free survival
were reported (level 1-),100 but a further meta-analysis
reported that the benefit of interferon was more evi-
dent in patients responding to combined interferon
and anthracycline-based polychemotherapy.101 In a
subsequent meta-analysis based on individual patient
data from ten randomized trials,102 adding interferon
to the initial chemotherapy did not significantly
improve the response rate; however, interferon signif-
icantly improve overall survival when associated with
a dose higher than 5 million units and a cumulative
dose over 36 million units (relatively intensive
chemotherapy). The Expert Panel judged that the tox-
icity of interferon when included in first-line
chemotherapy did not balance the possible survival
benefit. This conclusion was also grounded on quali-
ty-adjusted survival analysis and cost-effectiveness
analysis exploited in two studies.103,104
Rituximab was used as a single agent in untreated
patients with stage III-IV indolent NHL.105-108 Overall
response rates ranged from 72% to 100% and a
molecular response in peripheral blood was achieved
by 53%. At one year, 69% to 80% of patients were
free of progression, and at 3 years from 32% to 49%
were progression-free. After a median follow-up of 32
months, neither disease-free survival nor overall sur-
vival resulted significantly longer in patients random-
ized to rituximab than in those assigned to CNOP or
CHOP plus rituximab.108 No controlled study has
compared a strategy of watchful waiting or radiother-
apy with rituximab monotherapy in this subset of
patients.
First-line association, either concurrent or sequen-
tial, of rituximab with chemotherapy was explored in
candidates for treatment. Two randomized studies
recently provided evidence on the efficacy of ritux-
imab combined with CHOP or CVP regimens in
advanced-stage follicular lymphoma.109,110 The addi-
tion of rituximab to first line chemotherapy (CVP or
CHOP) significantly increased overall and complete
response rates and prolonged time to treatment fail-
ure. In both studies, the follow-up was shorter than 3
years and no data on overall survival have been pro-
vided. In addition, two other randomized trials pub-
lished in abstract form,111,112 confirmed the advantage
of combining rituximab with chemotherapy regimens
(CHVP+interferon and MCP respectively). Moreover,
two recent phase II studies reported a prolonged clin-
ical and molecular remissions in newly diagnosed
patients with indolent NHL treated with CHOP
chemotherapy combined with rituximab,113 and high
clinical and molecular response rates to rituximab in
combination with fludarabine chemotherapy.68,114
Although the chemotherapy regimens varied among
the studies, based on the evidence available on the
efficacy of adding rituximab to chemotherapy, the
Expert Panel judged it appropriate to combine ritux-
imab with conventional chemotherapy regimens in
first line treatment.
The optimal association of rituximab with
chemotherapy is still a matter of debate. The only
evidence was provided by a recent randomized study
in which concurrent administration provided better
progression-free survival than did sequential adminis-
tration.115 However, the Expert Panel judged this evi-
dence not sufficient to give recommendations.
A phase II trial (grade 2++) reported the results of
radio-immunotherapy with iodine I131 tositumomab
regimens as single initial treatment in 77 previously
untreated patients with follicular lymphoma.116 The
overall response was 95% (complete remission 75%)
with a molecular response rate of 80%. After a medi-
an follow up of 5.1 years, 59% were alive without
progression and hematologic toxicity was moderate.
Moreover, three phase II trials reported the results of
combination chemo-radio immunotherapy (iodine I131
tositumomab) regimens in previously untreated follic-
ular lymphoma patients, suggesting that this combi-
nation could be a highly effective and well tolerated
regimen for initial therapy of patients with follicular
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lymphoma.117-119 However, a comparison of long-term
outcomes with standard chemotherapy or with radio-
immunotherapy is not possible, yet. Therefore, the
Expert Panel deemed radio-immunotherapy appropri-
ate only in well-designed clinical trials.
Randomized phase III studies assessing frontline
autologous stem cell transplantation (SCT) were
recently reported by the GELA, GOLEAMS and
GLSG study group.120-122 The GELF94 trial reported a
12% better 7-year overall survival in 192 untreated
patients with follicular lymphoma and a high tumor
burden who received frontline CHOP and autologous
SCT (with total body irradiation conditioning), as
compared with 209 patients randomized to CHVP
and interferon.120 The GOLEAMS 064 trial, however,
did not report a significant advantage in overall sur-
vival of autologous SCT at a median 56 months of fol-
low-up, while 5-year event-free survival increased
from 37% to 59%.121 The randomized trial of the
German Low-grade Study Group (GLSG) showed
that consolidation with myeloablative
radiochemotherapy followed by autologous SCT,
after CHOP-like therapy, compared to conventional
interferon maintenance, prolonged progression-free
survival in 307 patients with follicular lymphoma in
first remission.122
None of these three randomized studies did a com-
parison of frontline autologous SCT with frontline
chemoimmunotherapy. Considering that no plateau
was evident in survival curves after autologous SCT
and that evidence on the role of chemoimmunother-
apy is rapidly growing, the Expert Panel considered
that first-line autologous SCT should be reserved to
patients enrolled into prospective clinical trials.
Molecular restaging
Several prospective (level 2+) studies documented
that the achievement of a sustained molecular
response after conventional chemotherapy with or
without rituximab was a favorable prognostic factor
and correlated with prolonged failure-free sur-
vival.113,114,116,123 Despite some conflicting results being
reported,124 the Expert Panel judged that it is appropri-
ate to assess molecular remission in patients who
achieve complete remission after frontline
chemotherapy.
Recommendations 
Before deciding the therapy for patients with indolent
NHL, lymphoid tissue should be tested for CD20 antigen
expression [grade D].
Patients with stage I-II disease and low-tumor burden
should receive external involved field radiotherapy only
[grade B], at the dose of 30-36 Gy. Adjuvant chemotherapy
is not recommended in these patients [grade D].
Patients with stage I-II disease and a high tumor burden
or an IPI score>1 or ILI score>2 or FLIPI>2 should receive
frontline chemotherapy plus radiotherapy [grade D].
Patients with stage III-IV disease and not candidates for
a watch and wait strategy, should be treated with frontline
chemotherapy [grade B].
Radiotherapy alone is not recommended for patients with
advanced stage disease [grade B], however, patients with
stage III disease and a low tumor burden may be treated
with external radiotherapy alone if they prefer to avoid
chemotherapy or if there is a contraindication to chemother-
apy. The long-term toxicity of radiotherapy should be dis-
cussed with the patient and the patient should be carefully
monitored [grade D].
Frontline chemotherapy, either single-agent alkylators,
anthracycline-based polychemotherapy or fludarabine-
based polychemotherapy, should be chosen according to the
characteristics of the patient and the disease [grade B].
Rituximab, either concurrent or sequential, should be
added to frontline conventional chemotherapy [grade A].
Younger patients should not receive single-agent alkylating
chemotherapy because it is not able to induce molecular
remission and it reduces stem cell mobilization potential
[grade C].
Interferon is not recommended as induction therapy, either
alone [grade A] or in association with chemotherapy [grade
A].
Molecular response should be checked at the end of first-
line therapy in all patients with an informative probe who
reach a complete clinical remission [grade D].
Maintenance therapy
Seven trials randomized a total of 1250 patients to
either interferon maintenance therapy or observation
only.75,96-98,125-129 The drug (3-5 MU three times weekly)
was administered for 1 or 2 years or until progression.
A statistically significant increase of progression-free
survival was found in a few studies,98,126,127 while only
one study126 was able to demonstrate an increase in
overall survival. Two meta-analyses100,101 pooled the
data of randomized trials employing interferon but
did not separately calculate the outcomes of mainte-
nance therapy, therefore the results cannot be applied
to the specific effect of interferon maintenance. A
recent meta-analysis102 deeply analyzed ten random-
ized trials and concluded that interferon could not
improve overall survival when administered as a
maintenance therapy. Moreover, long-term interferon
therapy severely impairs patients’ quality of life and
such a detrimental effect may offset the potential clin-
ical benefit.103 The Expert Panel agreed not to recom-
mend universal interferon maintenance therapy in
this clinical setting.
Preliminary results supported the positive role of
maintenance rituximab infusion on response duration
in patients with follicular lymphoma.130 Two random-
ized studies have been reported so far confirming
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these results.114,131 Recently, a Swiss trial132 showed that
prolonging rituximab monotherapy from 3 to 11
months induced a relevant prolongation of event-free
survival in 185 patients with follicular lymphoma,
67% of whom were chemotherapy-naïve. Another
randomized trial of 322 patients, only partially report-
ed at scientific meetings, was prematurely interrupted
because maintenance rituximab significantly pro-
longed progression-free survival after CVP with a 4-
year progression-free survival of 58% in the mainte-
nance arm versus 34% in the no-maintenance arm.133
Two phase II studies134,135 employed rituximab in asso-
ciation with interferon; however they did not allow
comparison with rituximab as single-agent therapy.
Rituximab was explored in patients with minimal
residual disease after autologous SCT:136,137 it proved to
be able to induce molecular response in more than
half of the patients and this response lasted more than
6 months. The Expert Panel judged that the real long-
term clinical benefits of rituximab in this setting
deserve more comparative studies with adequate fol-
low-up. 
Maintenance chemotherapy was assessed before
1990 by two randomized studies, showing that inter-
mittent chlorambucil or BCVP provided a significant
improvement in progression-free survival,138,139 with-
out advantage for overall survival. The Expert Panel
judged that myelotoxic therapies should be spared in
patients who may subsequently be candidates for
effective salvage therapies including chemo-immu-
notherapy or high-dose therapy with autologous
SCT.
Recommendations
Chemotherapy or interferon is not recommended as main-
tenance therapy in low grade NHL [grade A]. The use of rit-
uximab in the maintenance strategy should be considered
investigational.
Therapy for patients who do not achieve a complete
response to frontline therapy
Patients with a partial response
The Expert Panel found it difficult to pronounce on
the treatment of patients not achieving a complete
response after first-line therapy because very few
studies have specifically addressed this issue. Many
studies enrolled a mixed cohort of patients with
either partial response or no response hampering the
interpretation of the results.140-142 In principle, the
delivery of an alternative course of chemotherapy in
patients with a partial response, may allow further
tumor reduction along with the possibility of achiev-
ing a complete response. The sequential addition of
rituximab in patients achieving a partial response
after first-line anthracycline- or fludarabine-based
chemotherapy, was reported to increase overall
response rates to over 90% and complete response
rates from 50% to 80% in phase II studies.86,143-145
Therefore, the Expert Panel deemed rituximab a pos-
sible consolidation option for patients with indolent
NHL. However, even in the absence of strong evi-
dence, the Expert Panel agreed that an exception to
this indication was the case of non-follicular lym-
phoma with a high number of circulating CD20+ cells,
i.e. small lymphocytic lymphoma.
Indirect evidence supported the application of
frontline autologous SCT in those patients who did
not achieve complete remission after first-line thera-
py. The use of autologous SCT as a consolidation
treatment has been recently evaluated in a random-
ized trial: the study compares SCT to interferon in
patients with follicular lymphoma achieving a com-
plete or partial response after CHOP chemotherapy.122
The results of this trial showed that autologous SCT
significantly prolonged 5-year progression-free sur-
vival both in the whole study population (64.7% vs
33.3%) and in the subset with an initial partial
response (63% vs 32%). However, an increased risk
of secondary neoplasms has been observed that
might counter-balance the benefit of autologous
SCT.121,146 Thus, the Expert Panel judged that this
approach was to be reserved only to patients with
negative prognostic factors.
Finally, radioimmunoconjugates have been consid-
ered a consolidation option for patients with follicu-
lar lymphoma who have achieved a partial response
after chemotherapy: a phase II study (grade 2) in this
setting showed an increased rate of complete
response without a relevant increase of toxicity.147
Non-responding patients
Evidence from phase II studies (grade 2) supports
the conclusion that patients who do not respond to
single-agent alkylators as first-line therapy might ben-
efit from an anthracycline- or fludarabine-based
chemotherapy.84,141-143 However, stronger evidence
supports the use of rituximab, as reported by 13
phase II studies and a randomized trial.148 In refracto-
ry/relapsed patients, rituximab monotherapy pro-
duced overall response rates of 21% to 63%, and less
than 24% complete responses. Molecular response
was achieved in over 50% of bcl2+ patients, however
molecular response did not correlate with complete
responses.149 Association of rituximab with chemo-
therapy is much more effective than single-agent
therapy.150 In phase II studies enrolling patients with
relapsed/ resistant follicular lymphoma, the associa-
tion of CHOP-like or fludarabine-based poly-
chemotherapy with rituximab gave overall responses
rates ranging from 82% to 97%. Moreover, chemoim-
munotherapy with rituximab achieved molecular
response in 80-90% of bcl2+ patients. The elderly did
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not achieve lower response rates than the younger.
Two recent randomized trials in patients with
relapsed and refractory FL reported a prolonged pro-
gression-free survival with the addition of rituximab
to fludarabine, cyclophosphamide and mitoxantrone
(FCM)151 or MCP chemotherapy.152
A further therapeutic option in non-responding
patients is autologous SCT. Evidence on the use of
autologous SCT in primary refractory patients has
been derived from mixed cohorts also including
relapsed patients. The available studies provided evi-
dence that delaying high-dose therapy and SCT
impaired mobilization potential,63,64,153-157 and that the
outcomes after autologous SCT were heavily
impaired in chemorefractory patients.158-164
A high number of trials indicate that young patients
with a sibling donor should be candidates for allo-
geneic SCT as soon as they show non-response to
standard chemotherapy.165-173 The incidence of post-
transplant secondary myelodysplastic syndromes or
acute myeloid leukemia (sMDS/AML) is very
low;174,175 however, allogeneic SCT is associated with
an overall transplant-related mortality of about 20%
according to the latest reports175,176 and transplant-
related mortality was higher in chemorefractory
patients.177 Long-term molecular remissions are fre-
quent, and a survival plateau in patients alive at 2
years from transplant was reported.172-180 Positive pre-
dictors of overall survival were mainly the negative
predictors of transplant-related mortality, which had
the major impact on survival. As a matter of fact, age
lower than 40 years, a good performance status and
chemosensitivity all showed hazard ratios of about
0.5 at multivariate analysis.176 Radio-immunotherapy
is also a therapeutic option in patients not responding
to first-line chemotherapy. In refractory indolent NHL
b-emitting anti-CD20 antibodies, i.e. tositumomab
and ibritumomab, administered according to the
schedules reported in Appendix 1, produced an overall
response rate of 60%-70% and complete responses in
20%-35% of patients, as shown by several phase II
studies.181-190 Grade IV neutropenia occurred in 5% to
17% of the patients treated with tositumomab,182,184
and in 30% to 35% of those receiving ibritumomab;185
grade IV thrombocytopenia occurred in 3% of the
patients after tositumomab183 and 7% to 16% after
ibritumomab.187 Serious infections occurred in 5% to
7% of the patients.184,190 Nadir platelet and neutrophil
counts occurred 7-9 weeks after administration of the
radio-immunoconjugate.190 Similar rates of hemato-
logic complications were observed in younger and
older patients.185 The risk of severe complications
increased in patients with bone marrow involvement.
Long-term complications of radio-immunoconjugate
include sMDS, which occurred in 8.4% of the
patients treated with tositumomab.182 The annual
incidence rate of sMDS was estimated to be 1.4%
from a pooled analysis of 7 trials; however, in heavi-
ly pretreated patients in a large series, the incidence
rate was 3.8% per year and was associated with an
additional 2% per year risk of non-hematologic non-
skin cancers.191,192 Cytogenetic abnormalities in chro-
mosome 5 or 7 were found pre-treatment in nearly all
of the patients who subsequently developed
sMDS.191,192 Limited data are available on the rate of
sMDS after ibritumomab therapy: a 1.5% rate was
evident at a follow-up shorter than 2 years.185 Patients
treated with tositumomab must have their thyroid
stimulating hormone values monitored and receive
thyroid protection since elevated levels occur in 8.5%
of the patients, despite thyroid protection.184
No clinical trial specifically addressed patients who
achieved a partial response after frontline radiothera-
py nor patients progressing during watchful waiting:
the Expert Panel deemed that recommendations for
first-line therapy were appropriate for this group of
patients, too. 
Recommendations
Patients who achieved a partial remission after first-line
therapy may be considered for consolidation treatment with
one of the following options: rituximab, autologous SCT,
radioimmunoconjugates (either tositumomab or ibritu-
momab) [grade C]. 
Patients not responding to first-line chemotherapy should
receive further treatment provided that they are sympto-
matic, or have a threatened organ function, or a cytopenia
secondary to bone marrow infiltration, or massive bulky dis-
ease at presentation, or a steady progression over the last 6
months [grade D].
Patients not responding to first-line alkylating agent-
based chemotherapy can be offered an anthracycline- and/or
fludarabine-based regimen with rituximab [grade C].
Patients not responding to first-line anthracycline- or flu-
darabine-based chemotherapy should be offered high dose
chemotherapy and SCT (autologous or allogeneic) [grade
B]: if SCT is not feasible it is recommended that these
patients receive radioimmunoconjugates (either tositumomab
or ibritumomab) [grade C].
Therapy for relapsed patients
Histopathological transformation of low-grade fol-
licular lymphoma to large-cell aggressive NHL occurs
frequently in the course of follicular lymphoma, espe-
cially within the first 6 years from diagnosis.193-195
Transformed lymphomas have an aggressive disease
course193,197,198 and require a specific treatment (see next
section); therefore, the Expert Panel agreed that
histopathological reassessment is mandatory before
any treatment decision is made in relapsed patients.
Literature review identified 26 reports of patients
undergoing autologous SCT after relapse of an indo-
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lent NHL. Non-randomized studies provided evi-
dence that transplant-related mortality in patients 60-
70 years of age undergoing autologous SCT is similar
to that in younger patients, ranging from 0 to
10%.199–204 The major long-term complications of auto-
logous SCT were sMDS, occurring in 3% to 15% of
patients within 5 years after transplantation.205-211 The
lowest incidence rate of sMDS, derived from the
EBMT Working Party, was 3% at 5 years in nearly
5000 lymphoma patients.210 However, the incidence
reached up to 24% at 10 years and was higher in fol-
licular or indolent lymphoma than in aggressive
NHL.207,212,213 A randomized comparison provided
strong evidence that about 8% of patients with indo-
lent NHL undergoing myeloablative radiochemother-
apy followed by SCT could be expected to develop
sMDS, as compared with less than 1% of patients
receiving conventional therapy.213 The major predic-
tors of sMDS after transplantation are age,214,215 cumu-
lative dose of alkylating agents before transplanta-
tion,215-217 and abnormal pre-transplant cytogenetics.218
The last parameter had a very high negative predic-
tive power, since none of the patients with normal
cytogenetics developed sMDS after transplant; how-
ever, its positive predictive power ranged from 15%
to 85% in the few studies reported, since abnormal
cytogenetics interacted with other factors predictive
of the development of sMDS.218-221
Autologous SCT was shown to be superior to stan-
dard chemotherapy in six retrospective controlled
studies222-228 and in a randomized trial.229 The CUP
trial,229 comparing standard chemotherapy (CHOP) to
autologous SCT in relapsed follicular lymphoma, was
stopped prematurely because of poor patient accrual:
after 2 years of follow-up the trial showed a nearly
50% reduction of relapse rate and statistically signifi-
cant improvements in progression-free and overall
survival by using SCT (hazard ratio for overall sur-
vivaal, 0.43). Moreover, a similar conclusion was
reported by a randomized trial enrolling patients with
intermediate/high-grade NHL.230
At multivariate analysis, status of disease at trans-
plant was the best predictor for disease-free survival:
the largest cohort of patients with indolent NHL
undergoing autologous SCT reported 12-year overall
survival and disease-free survival were 61% (95% CI:
53-69%) and 37% (95% CI: 27-47%), respectively, in
419 patients with follicular lymphoma.211 Therefore,
the Expert Panel deemed evidence strong enough to
recommend autologous SCT in relapsed patients who
achieve a response to re-induction chemotherapy.
Only one study specifically reported the outcome of
patients with non-follicular indolent NHL after autol-
ogous SCT: among 21 patients the overall survival at
6 years was 68%.231 Several other reports did not dis-
tinguish between follicular and non- follicular indo-
lent NHL; therefore, the Expert Panel considered it
appropriate to translate the recommendations for fol-
licular lymphoma to other non- follicular indolent
NHL.
Conditioning with total body irradiation was
reported to increase the incidence of sMDS by up to
5-fold.215,232 Contrasting data were reported by retro-
spective studies comparing conditioning regimens
based or not on total body irradiation: one study
reported a detrimental effect on overall survival,233
while the opposite was shown for fractionated total
body iradiation in another study,234 and overall sur-
vival was not different in most of the reports.214,235-237
Conditioning strategies for autologous SCT have
recently incorporated radio-immunotherapy regi-
mens. A retrospective case-control study of 125
patients with follicular lymphoma reported lower
transplant-related mortality and higher overall sur-
vival (hazard ratio, 0.3) and progression-free survival
(hazard ration, 0.5) in patients conditioned with tosi-
tumomab, with no significant increase in the rate of
sMDS.238,239 The outcomes were apparently better in
patients conditioned with radio-immunoconjugates
than with total body irradiation;240 however, prospec-
tive controlled studies have not confirmed such a ben-
efit, yet. 
Lymphoma cells often contaminate bone marrow
and peripheral blood stem cell collections and may
contribute to relapse after autologous SCT.204 One
randomized and four high-quality retrospective
cohort studies reported the outcomes of in vitro purg-
ing with anti-B-cell monoclonal antibodies.175,227,233 The
most recent retrospective large cohort confirmed
prior reports205 and significant 26% and 32% reduc-
tions were observed in 5-year relapse rate and overall
survival, respectively, in patients receiving an in vitro
purged harvest. In contrast, the CUP trial229 reported
similar outcomes after purged and unpurged harvests
in 89 patients with follicular lymphoma, but the trial
was prematurely stopped after enrolling only 89
patients, so it was underpowered.
More recently, in vivo purging was achieved by
administering rituximab prior to autologous SCT.
Three-year relapse-free survival and 2-year progres-
sion-free survival rates were 84% and 97%, respec-
tively, in the most recent studies.241,243 Studies reported
a lower harvest yield, a longer time to engraftment
and later immune reconstitution in patients undergo-
ing autologous SCT after having received rituximab
in the 6 preceding months,243 while others did not
detect such detrimental effects.244-247 The Expert Panel
judged that definitive data on the efficacy of ritux-
imab on purging are not available due to very differ-
ent schedules and patient selection (often including
mantle-cell lymphomas) among the studies and due
to the lack of controlled studies. 
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Table 2. The complete set of recommendations for indolent non-Hodgkin’s lymphomas (NHL).
Treatment can be safely deferred without disadvantage to survival for patients with stage III-IV disease, provided that none of the following features occurs: systemic
symptoms, high tumor burden, extranodal disease, cytopenia due to marrow involvement, spleen involvement, leukemic phase, serous effusion, erythrocyte
sedimentation rate > 20 mm/h, high lactate dehydrogenase levels [grade A].
A policy of watchful waiting is particularly advisable in elderly patients (> 70 years) with the above characteristics [grade B].
Patients with stage I-II disease should not be managed with a frontline strategy of watchful waiting; however elderly patients with stage I disease and no symptoms
whose lactate dehydrogenase level is not elevated may be safely observed without treatment, provided that there is no residual disease after excisional biopsy
[grade D].
Before deciding the therapy for patients with indolent NHL, lymphoid tissue should be tested for CD20 antigen expression [grade B].
Patients with stage I-II disease and low-tumor burden should receive external involved field radiotherapy only [grade B], at the dose of 30-36 Gy.
Adjuvant chemotherapy is not recommended in these patients [grade D].
Patients with stage I-II disease and a high tumor burden or an IPI score>1 or ILI score>2 or FLIPI>2 should receive frontline chemotherapy plus radiotherapy
[grade D].
Patients with stage III-IV disease and not candidates for a watch and wait strategy, should be treated with frontline chemotherapy [grade B].
Radiotherapy alone is not recommended for patients with advanced stage disease [grade B], however, patients with stage III disease and a low tumor burden may
be treated with external radiotherapy alone if they prefer to avoid chemotherapy or if there is a contraindication to chemotherapy. The long-term toxicity of radiother-
apy should be discussed with the patient and the patient should be carefully monitored [grade D].
Frontline chemotherapy, either single-agent alkylators, anthracycline-based polychemotherapy or fludarabine-based polychemotherapy, should be chosen according
to the characteristics of the patient and the disease [grade B].
Rituximab, either concurrent or sequential, should be added to frontline conventional chemotherapy [grade A]. Younger patients should not receive single-agent
alkylating chemotherapy because it is not able to induce molecular remission and it reduces stem cell mobilization potential [grade C].
Interferon is not recommended as induction therapy, either alone [grade A] or in association with chemotherapy [grade A].
Molecular response should be checked at the end of first-line therapy in all patients with an informative probe who reach a complete clinical remission
[grade D].
Chemotherapy or interferon is not recommended as maintenance therapy in low grade NHL [grade A]. The use of rituximab in the maintenance strategy should be
considered investigational. Patients who have achieved a partial remission after first-line therapy may be considered for consolidation treatment with one of the
following options: rituximab, autologous stem cell transplantation (SCT), radioimmunoconjugates (either tositumomab or ibritumomab) [grade C].
Patients not responding to first-line chemotherapy should receive further treatment provided that they are symptomatic, or have a threatened organ function, or a
cytopenia secondary to bone marrow infiltration, or massive bulky disease at presentation, or steady progression over the last 6 months [grade D].
Patients not responding to first-line alkylating agent-based chemotherapy can be offered an anthracycline- and/or fludarabine-based regimen with rituximab
[grade C].
Patients not responding to first line anthracycline- or fludarabine-based chemotherapy should be offered high dose chemotherapy and SCT (autologous or allogeneic)
[grade B]: if SCT is not feasible it is recommended that these patients receive radioimmunoconjugates (either tositumomab or ibritumomab) [grade C].
Relapsed patients should undergo new histologic documentation prior to a decision on salvage therapy being taken [grade D].
Patients should receive further treatment provided that they are symptomatic, or have a threatened organ function, or a cytopenia secondary to bone marrow
infiltration, or massive bulk at presentation, or steady progression over the preceding 6 months [grade D].
Patients who relapse after a first-line therapy not containing either anthracyclines or fludarabine should receive antracycline- or fludarabine-based polychemotherapy
associated with rituximab [grade B].
Patients under 65 years old with extended relapses after a first-line therapy containing either anthracyclines or fludarabine should be treated with high-dose therapy
and autologous SCT [grade B].
Autologous SCT should be performed upon achievement of at least partial remission with an appropriate cytoreductive treatment [grade D]. It is recommended that
any procedure capable of producing a lymphoma-free graft is used [grade B].
Molecular response should be checked after autologous SCT in all patients with an informative probe and a complete clinical remission [grade D]. Periodic follow-up
monitoring of molecular remission after autologous SCT cannot be recommended for current clinical practice outside clinical studies [grade D].
If autologous SCT is not feasible (poor mobilization of peripheral stem cells or partial remission not achieved before SCT) and a fully matched family donor is
available, it is recommended to perform allogeneic SCT [grade C].
Patients under 65 years old with a relapse after autologous SCT and a fully matched family donor should also receive allogeneic SCT [grade C].
For patients who are refractory to or relapse after autologous SCT, or for whom autologous SCT is not feasible (poor mobilization of peripheral stem cells or partial
remission not achieved before SCT), but without a family donor, a search for an unrelated donor may be performed according to the indications of the National Bone
Marrow Registry, provided that the patients are <55 years old [grade D].
Myeloablative allogeneic SCT should be reserved to very selected patients aged < 45 years [grade D].
Molecular response should be checked after allogeneic SCT in all patients with an informative probe and a complete clinical remission: periodic monitoring of
molecular remission should be performed [grade D].
Radio-immunoconjugates are recommended for patients who relapse after anthracycline- or fludarabine-containing first-line therapy and for whom SCT is not feasi-
ble, or who relapse after SCT [grade C].
Transformed lymphoma should be treated in the same way as diffuse large cell lymphoma [grade D].
The number of bcl2+ circulating cells decreases after
autologous SCT249 and patients with a molecular
response to autologous SCT have an 87% lower risk
of relapse,250-252 the chance of relapse being proportion-
al to the quantity of polymerase chain reaction-posi-
tive cells found in peripheral blood.248 A negative
polymerase chain reaction status post-transplant also
reduced the chance of death by 75% and was more
relevant to overall survival than was the polymerase
chain reaction status of the reinfused graft.205
Therefore, the Expert Panel deemed that the evidence
was sufficient to recommend that molecular response
status should be verified after completion of the
transplant program. Observational studies have docu-
mented that the number of circulating bcl2+ cells
remained stable during complete remission and
increased at relapse.248-251 However, the Expert Panel
did not agree on the clinical utility of periodic moni-
toring of molecular remission due to the lack of direct
evidence. Therefore, this strategy was deemed appro-
priate only in clinical trials.
Allogeneic SCT proved to have a high benefit-to-
risk ratio, especially in chemosensitive young patients
(for detailed analysis see previous section).252,253 Peripheral
stem cells from sibling donors are the preferred source
of hematopoietic progenitors since translated evi-
dence from several randomized trials enrolling mixed
cohorts with lymphoproliferative diseases,254 showed
better engraftment after such transplants, without an
increased risk of acute graft-versus-host disease and
possible longer disease-free survival and overall sur-
vival. No randomized trial supported the superiority
of reduced intensity conditioning over conventional
conditioning, although retrospectively collected data
on transplant-related mortality in mixed NHL cohorts
might suggest such an effect.255,256 Further data on the
possible role of alemtuzumab in conditioning regi-
mens for allogeneic SCT are still awaited.
After allogeneic SCT for NHL, the risk of relapse is
higher in patients who do not achieve a molecular
response.179 Even though based on evidence derived
from only one non-randomized study, the Expert
Panel judged it relevant to refine the prognosis of
transplanted patients by assessing the molecular
response status after allogeneic SCT also in routine
clinical practice.
Radio-immunoconjugates are effective in relapsed
patients also outside a transplantation procedure:
durable reponses were shown at long-term follow-up
in large cohorts of patients with relapsed/ refractory
follicular NHL treated with ibritumomab, tiuxetan or
tositumomab.189,190,257 The overall response rates were
81-97% with tositumomab 185,259,260 and 68%-89%
with ibritumomab,187 irrespectively of age. Complete
responders maintained their response status for over
4-5 years 185,258 and median response duration was
longer than that to the previous line of therapy,
approaching 2 years in a recent update of the random-
ized trial with ibritumomab.189,190 Molecular response
was also achieved in 82%-94% of the patients after
radio-immunoconjugate therapy;261,262 however, a pro-
longed response in patients with a molecular
response was reported only for tositumomab.
Ibritumomab was also more effective than rituximab
as a single-agent in a randomized trial.189 Response
rates to radio-immunoconjugates depended, at multi-
variate analysis, on the number of previous lines of
treatment,187 number of nodes involved and bulky dis-
ease.148,187,188
Recommendations 
Relapsed patients should undergo new histologic docu-
mentation prior to a decision on salvage therapy being taken
[grade D].
Patients should receive further treatment provided that
they are symptomatic, or have a threatened organ function,
or a cytopenia secondary to bone marrow infiltration, or
massive bulk at presentation, or steady progression over the
preceding 6 months [grade D].
Patients who relapse after a first-line therapy not contain-
ing either anthracyclines or fludarabine should receive
anthracycline- or fludarabine-based polychemotherapy
associated with rituximab [grade B].
Patients under 65 years old with extended relapses after
a first-line therapy containing either anthracyclines or flu-
darabine should be treated with high-dose therapy and
autologous SCT [grade B].
Autologous SCT should be performed upon achievement
of at least partial remission with an appropriate cytoreduc-
tive treatment [grade D]. It is recommended that any proce-
dure capable of producing a lymphoma-free graft is used
[grade B].
Molecular response should be checked after autologous
SCT in all patients with an informative probe and a com-
plete clinical remission [grade D]. Periodic follow-up moni-
toring of molecular remission after autologous SCT cannot
be recommended for current clinical practice outside clinical
studies [grade D].
If autologous SCT is not feasible (poor mobilization of
peripheral stem cells or partial remission not achieved before
SCT) and a fully matched family donor is available, it is
recommended to perform allogeneic SCT [grade C]. Patients
under 65 years old with a relapse after autologous SCT and
a fully matched family donor should also receive allogeneic
SCT [grade C].
For patients who are refractory to or relapse after autolo-
gous SCT, or for whom autologous SCT is not feasible (poor
mobilization of peripheral stem cells or partial remission not
achieved before SCT), but without a family donor, a search
for an unrelated donor may be performed according to the
indications of the National Bone Marrow Registry, provided
that the patients are <55 years old [grade D].
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Myeloablative allogeneic SCT should be reserved to very
selected patients aged < 45 years [grade D].
Molecular response should be checked after allogeneic
SCT in all patients with an informative probe and a com-
plete clinical remission: periodic monitoring of molecular
remission should be performed [grade D].
Radio-immunoconjugates are recommended for patients
who relapse after anthracycline- or fludarabine-containing
first-line therapy and for whom SCT is not feasible, or who
relapse after SCT [grade C].
Therapy for transformed lymphoma
Histopathological transformation of low-grade fol-
licular lymphoma to large-cell aggressive NHL is an
event occurring in 15-32% of the patients:193,194,198 the
incidence appears to reach a plateau by 6 years after
the diagnosis of follicular lymphoma,193,195 and the
median time to transformation is 66 months.196 High
b-2-microglobulin serum levels at diagnosis and fail-
ure to achieve compete remission after first-line ther-
apy predict a higher risk of transformation.193 The
prognosis for transformed lymphoma is generally
poor, the median survival after transformation being
about 10 months193,197,198 thus accounting for a large
proportion of deaths in patients with follicular lym-
phoma. Disease-free survival in transformed NHL
treated with standard chemotherapy was poorer than
that in de novo diffuse large-cell lymphoma,263 but in
one study overall survival seemed better than that in
primarily aggressive NHL.264 Young patients with lim-
ited disease who were chemosensitive experienced
prolonged survival.193,196,265 Therefore, data did not
show a relevantly different behavior between the two
types of large-cell lymphoma.198 Age, response to sal-
vage therapy, B symptoms, lactate dehydrogenase
values, bone marrow involvement, stage, no prior
chemotherapy, and early transformation were all pre-
dictive factors for survival after transforma-
tion.193,196,198,266
The median rate of overall survival after autologous
SCT was reported to be 40-60% at 4-5 years,193,198,234,267-
269 and about 30% of over 200 patients included in
published series were alive without disease at 5
years.193,198,268-270 Survival after autologous SCT was not
dissimilar to that reported for patients with non-
transformed indolent NHL and primarily aggressive
NHL undergoing autologous SCT.229,271,272 Tandem
transplantation was attempted in three patients with
transformed lymphoma within a series of patients
with refractory/relapsed high-grade NHL:273 all the
three patients were relapse-free at 32-54 months. 
The literature on outcomes of allogeneic SCT in
transformed indolent NHL was judged inconsistent
by the Expert Panel since cases with aggressive NHL274
and with indolent NHL were aggregated.276 Successful
results have been reported in selected patients, a pro-
portion of whom achieved long-term disease-free sur-
vival.224,276-279 The results appeared to be particularly
poor for the subset of patients with both the bcl-2 and
the c-myc translocations, and no effective regimen
was reported.279-280 Conversely, high overall response
rates, ranging from 50% to 80%, and an acceptable
safety were reported in patients with transformed
disease and <25% bone marrow involvement who
were treated with ibritumomab and tositu-
momab,183,186,258 and also with rituximab therapy.156
Recommmendations
Transformed lymphoma should be treated in the same
way as diffuse large cell lymphoma [grade D].
Discussion
In this work, a systematic review of research litera-
ture and its grading for quality provided the evidence
base to be used for producing recommendations on
the treatment of nodal indolent NHL (Table 2).
However, to adhere to the quality standards for
guideline production,281,282 the practice guidelines pro-
duction of SIE, SIES and GITMO comprised interpre-
tation and consensus on the evidence by the mem-
bers of an Expert Panel and a consensus phase for rec-
ommendations on key clinical questions not support-
ed by good evidence. The theoretical value of the
experts’ consensus approach to influencing practice is
the assumption that such knowledgeable experts
have an implicit and comprehensive mastery of the
scientific and practical information that would yield
the most appropriate recommendations. With this
conceptual framework, the results of this project
mostly adhered to the quality items produced by
AGREE.281 The only exceptions are that patients’
views and preferences have been seldom explicitly
formulated in the recommendations, a pilot applica-
tion of the guideline has not been attempted and a
monitoring or audit process has not been initiated.
However, these guidelines have been externally
reviewed by three expert radiotherapists and three
senior hematologists, i.e. the presidents of the scien-
tific societies endorsing the present guidelines. We are
also aware that the potential cost implications of
applying the recommendations have only been
implicitly considered when formulating recommen-
dations for high-cost drugs or procedures. 
The present guidelines are focused on the most rel-
evant clinical questions in the complex therapeutic
pathway of indolent NHL, but are also aimed at sup-
porting a rational use of novel technologies still under
evaluation, such as monoclonal antibodies, radio-
immunoconjugates and stem cell transplantation. The
guidelines therefore cover a large domain including
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the decision on how to approach first-line therapy,
and the treatment of refractory, relapsed and trans-
formed lymphoma. Furthermore, different recom-
mendations have been formulated for diverse clinical
scenarios, making the recommendations patient-spe-
cific. However, neither supportive therapy, i.e. hema-
topoietic growth factors, nor therapies for lymph-
oma-related complications, i.e. drugs for lymphoma-
related autoimmune disorders, were specifically
addressed by the present guidelines, since these issues
belong more generally to supportive care in the field
of hemato-oncology.
These guidelines agree with the NCCN guide-
lines,283 but are at variance with the ESMO guide-
lines284 in recommending the use of locoregional ra-
diotherapy alone as front-line therapy for selected
stage I-II patients. The Expert Panel interpreted the
evidence as not supporting the use of chemotherapy
in these patients. None of the studies that analyzed
this issue reported a better overall survival for com-
bined modality treatment and some studies, reporting
a better progression-free survival, enrolled a large pro-
portion of patients with aggressive lymphomas. 
Both the NCCN283 and the present guidelines under-
line the difficulty in giving a definite recommendation
on first line treatment in advanced stage indolent lym-
phomas so far. Many options are available for the ini-
tial treatment. Different types of chemotherapy regi-
mens (alkylating single agent, combinations with or
without anthracyclines, fludarabine-containing regi-
mens) have been used with similar results. Thus, the
choice of initial therapy largely depends on clinical
factors such as age, site and extent of disease, comor-
bidities, pace of the disease, and the chance of future
transplantation options. 
The present guidelines provide specific and limited
frontline treatment options for stage III-IV patients:
single-agent alkylators were reserved to the elderly
patients, while younger patients were recommended
not to receive this treatment in order to avoid impair-
ment of peripheral blood stem cell mobilization for
possible future salvage autologous stem cell trans-
plantation.
The Expert Panel succeeded in providing some rules
for treatment prioritization in second and further
lines. In particular, candidates for autologous and allo-
geneic SCT are clearly defined, as are the indications
for the use of radio-immunoconjugates. Finally, these
guidelines fully incorporate the recent data on the use
of rituximab and non-myeloablative allogeneic SCT
and provide up-to-date recommendations on specific
transplantation procedures. In conclusion, the SIE,
SIES and GITMO guidelines represent a further effort
of the scientific community to meet clinical needs and
improve the quality of care for lymphoma patients.
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